Alfresa Holdings Corporation Financial Summary for the Second Quarter (Interim) of the Fiscal Year Ending March 2027

Overview of Results

Alfresa Holdings Corporation's consolidated results for the second quarter (interim period) of the fiscal year ending March 2027 recorded net sales of 1,582,760 million yen (a 3.5% increase year-on-year). However, operating income was 13,029 million yen (YoY -19.6%), ordinary income was 14,380 million yen (YoY -17.8%), and interim net income attributable to owners of the parent was 8,240 million yen (YoY -28.5%), representing declines. Factors affecting results include negative impacts from drug price revisions, increases in logistics and other costs, and startup expenses related to new drug development and capital expenditures. The full-year forecast remains unchanged, and recovery of performance will require balancing cost controls with growth investments. By segment, prescription pharmaceutical wholesale saw revenue growth, but manufacturing and logistics cost increases and drug price effects compressed profit margins.

Capital Policy and Outlook

The Company will continue share buybacks to improve capital efficiency. Treasury stock at the end of the interim period is approximately 35.9 hundred million yen, and the dividend forecast remains an annual 71 yen. The Company will continue to provide information to institutional investors through supplementary materials and briefings. The launch of new businesses in regenerative medicine and CRO areas continues, and efforts are underway to strengthen the business base in the Kyushu region and enhance cross-group strategic functions. In 2026, the Company realized business integrations through multiple consolidated subsidiaries and partnerships, and will continue to focus on integrated group-wide strengthening centered on TSCS.